Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Sperger JM
,
Emamekhoo H
,
McKay RR
,
Stahlfeld CN
,
Singh A
,
Chen XE
,
Kwak L
,
Gilsdorf CS
,
Wolfe SK
,
Wei XX
,
Silver R
,
Zhang Z
,
Morris MJ
,
Bubley G
,
Feng FY
,
Scher HI
,
Rathkopf D
,
Dehm SM
,
Choueiri TK
,
Halabi S
,
Armstrong AJ
,
Wyatt AW
,
Taplin ME
,
Zhao SG
,
Lang JM
.
???displayArticle.abstract???
PURPOSE: Nearly all men with prostate cancer treated with androgen receptor (AR) signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including constitutive activation of the AR pathway, driven by AR genomic structural alterations, expression of AR splice variants (AR-Vs), or loss of AR dependence and lineage plasticity termed neuroendocrine prostate cancer. Understanding these de novo acquired ARSI resistance mechanisms is critical for optimizing therapy.
MATERIALS AND METHODS: A novel liquid biopsy technology was used to collect mRNA from circulating tumor cells (CTCs) to measure expression of AR-Vs, AR targets, and neuroendocrine prostate cancer markers. An institutional review board-approved prospective cohort (N = 99) was used to identify patterns of gene expression. Two prospective multicenter phase II clinical trials of ARSIs for men with castration-resistant prostate cancer (ClinicalTrials.gov: NCT01942837 [enzalutamide, N = 21] and NCT02025010 [abiraterone, N = 27]) were used to further validate these findings.
RESULTS: Hierarchical clustering of CTC transcripts identified two distinct clusters. Cluster 2 (C2) exhibited increased expression of AR-regulated genes and was associated with worse overall survival (median 8.6 v 22.4 months; P < .01; hazard ratio [HR] = 3.45 [1.9 to 6.14]). In multivariable analysis, C2 was prognostic independent of other clinicopathologic variables. AR-V status was not significant when accounting for C2. Upon further validation in pooled multicenter phase II trials, C2 was associated with worse overall survival (15.2 months v not reached; P < .01; HR = 8.43 [2.74 to 25.92]), prostate-specific antigen progression-free survival (3.6 v 12 months; P < .01; HR = 4.64 [1.53 to 14.11]), and radiographic progression-free survival (2.7 v 40.6 months; P < .01; HR = 4.64 [1.82 to 17.41]).
CONCLUSION: We demonstrate that a transcriptional profile detectable in CTCs obtained from liquid biopsies can serve as an independent prognostic marker beyond AR-V7 in patients with metastatic prostate cancer and can be used to identify the emergence of multiple ARSI resistance mechanisms. This is currently being investigated in additional prospective trials.
Aggarwal,
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
2014,
Pubmed
Aggarwal,
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
2019,
Pubmed
Aggarwal,
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
2018,
Pubmed
Annala,
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
2018,
Pubmed
Antonarakis,
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
2016,
Pubmed
Antonarakis,
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
2014,
Pubmed
Armstrong,
New treatment options in castration-resistant prostate cancer.
2015,
Pubmed
Armstrong,
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
2018,
Pubmed
Armstrong,
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
2019,
Pubmed
Arora,
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
2013,
Pubmed
Asangani,
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
2016,
Pubmed
Bastos,
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
2018,
Pubmed
Beer,
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
2017,
Pubmed
Beltran,
Aggressive variants of castration-resistant prostate cancer.
2014,
Pubmed
Beltran,
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
2016,
Pubmed
Beltran,
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
2020,
Pubmed
Beltran,
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
2016,
Pubmed
Céraline,
Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.
2004,
Pubmed
Dang,
Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer.
2020,
Pubmed
Dehm,
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
2008,
Pubmed
Fizazi,
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
2019,
Pubmed
Harris,
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
2009,
Pubmed
Henzler,
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.
2016,
Pubmed
Hu,
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
2012,
Pubmed
Joseph,
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
2013,
Pubmed
Kohli,
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
2017,
Pubmed
Korpal,
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
2013,
Pubmed
Labrecque,
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
2019,
Pubmed
Li,
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.
2020,
Pubmed
Li,
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.
2011,
Pubmed
Luo,
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
2018,
Pubmed
Markowski,
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.
2017,
Pubmed
McKay,
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
2019,
Pubmed
Mohler,
Prostate Cancer, Version 1.2016.
2016,
Pubmed
Quigley,
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
2018,
Pubmed
Robinson,
Integrative clinical genomics of advanced prostate cancer.
2015,
Pubmed
Scher,
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
2009,
Pubmed
Scher,
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
2015,
Pubmed
Scher,
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
2016,
Pubmed
Scher,
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
2017,
Pubmed
Scher,
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
2017,
Pubmed
Smith,
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
2018,
Pubmed
Sperger,
Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation.
2017,
Pubmed
Strotman,
Selective nucleic acid removal via exclusion (SNARE): capturing mRNA and DNA from a single sample.
2013,
Pubmed
Tibshirani,
Diagnosis of multiple cancer types by shrunken centroids of gene expression.
2002,
Pubmed
Viswanathan,
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
2018,
Pubmed
Welti,
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
2018,
Pubmed
Yu,
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
2014,
Pubmed
Zhao,
The DNA methylation landscape of advanced prostate cancer.
2020,
Pubmed
de Bono,
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
2008,
Pubmed